Atika Capital Management LLC Purchases 64,419 Shares of DBV Technologies S.A. $DBVT

Atika Capital Management LLC raised its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 31.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 271,300 shares of the company’s stock after acquiring an additional 64,419 shares during the period. Atika Capital Management LLC’s holdings in DBV Technologies were worth $5,667,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Allworth Financial LP bought a new position in DBV Technologies during the 4th quarter worth approximately $32,000. Royal Bank of Canada purchased a new position in shares of DBV Technologies in the fourth quarter valued at about $34,000. GAMMA Investing LLC raised its stake in shares of DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after acquiring an additional 744 shares during the last quarter. Truvestments Capital LLC boosted its holdings in shares of DBV Technologies by 71.3% during the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after purchasing an additional 1,620 shares during the period. Finally, Persistent Asset Partners Ltd bought a new position in DBV Technologies during the 4th quarter valued at approximately $115,000. 71.74% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Citizens Jmp lifted their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Guggenheim reissued a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a research report on Monday, May 4th. Finally, Weiss Ratings downgraded DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Stock Performance

NASDAQ DBVT opened at $13.86 on Friday. The business’s fifty day moving average is $16.67 and its 200 day moving average is $19.33. The company has a market capitalization of $820.65 million, a PE ratio of -3.95 and a beta of -0.95. DBV Technologies S.A. has a fifty-two week low of $8.51 and a fifty-two week high of $26.18.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.48). DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%.The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.90 million. On average, sell-side analysts forecast that DBV Technologies S.A. will post -2.05 EPS for the current year.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.